With the motivation of finding a solution to the unmet needs of patients with different types of cancer, PharmaMar announces the start of a Phase I clinical study with PM14, a new antitumor compound resulting from the company´s internal investigation program for the treatment of patients with advanced solid tumors.
An investigational treatment that mimics a key clotting enzyme is effective, safe, and may one day eliminate the need for blood products for people with the rare, life-threatening blood disease hereditary thrombotic thrombocytopenic purpura (TTP), according to a study published online in Blood, the Journal of the American Society of Hematology (ASH).
Three interventions designed for follow up of patients who are identified with suicide risk in hospital emergency departments save lives and are cost effective relative to usual care. A study led by researchers at the National Institute of Mental Health (NIMH) modelled the use of the approaches in emergency departments and found that all three interventions compare favorably with a standard benchmark of cost-effectiveness used in evaluating healthcare costs. NIMH is part of NIH.
PharmaMar has presented during the European Society for Medical Oncology congress (ESMO), held in Madrid, positive results of PM1183 (lurbinectedin) in a cohort of 36 patients as monotherapy in patients with advanced and relapsed small-cell lung cancer (SCLC).
The U.S. Food and Drug Administration today granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease. It is the first treatment approved in the United States for the treatment of Chagas disease.
Clinical trials are fundamental to the development of new treatments for cancer, yet the annual accrual to cancer clinical trials worldwide is low, estimated at three to five percent. A nationwide study in Ireland, the preliminary results of which are to be presented at the ESMO 2017 Congress in Madrid, shows that although most oncology patients consider it important to have clinical trials available, many struggle with the central concepts that underpin trial methodology.
Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.